Influence of PXR Haplotype Variants on Paclitaxel and Docetaxel Pharmacokinetics and Pharmacodynamics in Asian Cancer Patients

被引：0
|
作者：
Chowbay, Balram [1 ]
Sandanaraj, Edwin [1 ]
Lal, Suman [1 ]
Wang Zhenping [1 ]
Teck, Lim Wan [2 ]
Siang, Ang Cher [2 ]
Lee, Edmund [3 ]
Huat, Tan Eng [2 ]
机构：
[1] Natl Canc Ctr, Div Med Sci, Clin Pharmacol Lab, Singapore 117548, Singapore
[2] Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore
[3] Natl Univ Singapore, Dept Pharmacol, Singapore, Singapore
来源：
DRUG METABOLISM REVIEWS | 2009年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
123
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [31] Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients
    Peter Nygren
    Kenneth Hande
    Kevin J. Petty
    Margaret Fedgchin
    Kristien van Dyck
    Anup Majumdar
    Debbie Panebianco
    Marina de Smet
    Tuli Ahmed
    M. Gail Murphy
    Keith M. Gottesdiener
    Veronique Cocquyt
    Simon van Belle
    Cancer Chemotherapy and Pharmacology, 2005, 55 : 609 - 616
  • [32] Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites
    Hidenori Tamegai
    Teruo Kaiga
    Mitsugu Kochi
    Masashi Fujii
    Noriaki Kanamori
    Yoshiaki Mihara
    Tomoya Funada
    Hiroko Shimizu
    Daijo Jinno
    Tadatoshi Takayama
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 727 - 731
  • [33] Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer
    Uday B. Dandamudi
    Laurel M. Adams
    Brendan Johnson
    John Bauman
    Shannon Morris
    Sharon Murray
    R. Timothy Webb
    Elaina Gartner
    Raymond Hohl
    Lionel D. Lewis
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 783 - 790
  • [34] Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer
    Dandamudi, Uday B.
    Adams, Laurel M.
    Johnson, Brendan
    Bauman, John
    Morris, Shannon
    Murray, Sharon
    Webb, R. Timothy
    Gartner, Elaina
    Hohl, Raymond
    Lewis, Lionel D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 783 - 790
  • [35] Population pharmacokinetics of weekly docetaxel in patients with advanced cancer
    Slaviero, KA
    Clarke, SJ
    McLachlan, AJ
    Blair, EYL
    Rivory, LP
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (01) : 44 - 53
  • [36] Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites
    Tamegai, Hidenori
    Kaiga, Teruo
    Kochi, Mitsugu
    Fujii, Masashi
    Kanamori, Noriaki
    Mihara, Yoshiaki
    Funada, Tomoya
    Shimizu, Hiroko
    Jinno, Daijo
    Takayama, Tadatoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 727 - 731
  • [37] Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients
    Nygren, P
    Hande, K
    Petty, KJ
    Fedgchin, M
    van Dyck, K
    Majumdar, A
    Panebianco, D
    de Smet, M
    Ahmed, T
    Murphy, MG
    Gottesdiener, KM
    Cocquyt, V
    van Belle, S
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (06) : 609 - 616
  • [38] Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients - The influence of cardiac output
    Kuipers, JA
    Boer, F
    Olofsen, E
    Bovill, JG
    Burm, AGL
    ANESTHESIOLOGY, 2001, 94 (01) : 47 - 55
  • [39] Docetaxel in paclitaxel-pretreated advanced breast cancer patients
    Nisticò, C
    Vaccaro, A
    Milella, M
    D'Ottavio, AM
    Garufi, C
    Rosati, N
    Papaldo, P
    Tropea, F
    Zappalà, A
    Terzoli, E
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S326 - S327
  • [40] EFFECT OF CASOPITANT, A NOVEL NK-1RECEPTOR ANTAGONIST, ON THE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF DOCETAXEL IN CANCER PATIENTS (PTS)
    Dandamudi, U. B.
    Balan, S. B.
    Gartner, E. M.
    Webb, T. R.
    Hohl, R. J.
    Adams, L. M.
    Bauman, J.
    Johnson, B.
    Murray, S.
    Morris, S.
    Lewis, L. D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S45 - S45
12345